Deerfield Mgmt Reports 545,455 Shared Shares in Edgewise Therapeutics

TL;DR

**Deerfield Mgmt still holds 545,455 shares of Edgewise Therapeutics, signaling continued institutional interest.**

AI Summary

Deerfield Mgmt, L.P. and its affiliated entities, including Deerfield Management Company, L.P., have filed an amended SC 13G/A for Edgewise Therapeutics, Inc. (EWGS), indicating a shared voting and dispositive power over 545,455 shares of Common Stock as of January 23, 2024. This filing updates their previous disclosures and signals that Deerfield continues to hold a significant, albeit potentially adjusted, stake in Edgewise Therapeutics. For investors, this matters because Deerfield is a major institutional investor, and their continued holding suggests confidence in the company's future, while any reduction from prior filings could signal a shift in their investment thesis.

Why It Matters

This filing shows that a major institutional investor, Deerfield Mgmt, maintains a significant stake in Edgewise Therapeutics, which can influence stock stability and investor sentiment.

Risk Assessment

Risk Level: low — This is an amendment to a routine disclosure, indicating no immediate new risks but rather an update on an existing institutional holding.

Analyst Insight

Investors should note Deerfield Mgmt's continued significant holding in Edgewise Therapeutics, as it suggests ongoing institutional interest. While this filing doesn't indicate a new position, it confirms a major player's involvement, which can be a positive signal for long-term stability. However, without knowing the previous holding, it's hard to determine if this is an increase or decrease.

Key Numbers

• 545,455 — Shares Beneficially Owned (Represents the shared voting and dispositive power of Deerfield Mgmt, L.P. in Edgewise Therapeutics, Inc.)
• January 23, 2024 — Date of Event (The specific date that triggered the requirement for this filing.)
• 28036F105 — CUSIP Number (Unique identifier for Edgewise Therapeutics, Inc. Common Stock.)

Key Players & Entities

• Deerfield Mgmt, L.P. (company) — reporting person with shared voting and dispositive power
• Edgewise Therapeutics, Inc. (company) — the issuer of the securities
• Deerfield Management Company, L.P. (company) — group member of the reporting entity
• Flynn James E (person) — filed by

Forward-Looking Statements

• Deerfield Mgmt, L.P. will maintain a significant stake in Edgewise Therapeutics, Inc. for the foreseeable future. (Deerfield Mgmt, L.P.) — medium confidence, target: Q3 2024

FAQ

Filing Documents

• e619222_sc13ga-edgewise.htm (SC 13G/A) — 130KB
• 0001193805-24-000117.txt ( ) — 132KB

(a)

Item 1(a). Name of Issuer: Edgewise Therapeutics, Inc.

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 3415 Colorado Ave. Boulder, Colorado 80303

(a)

Item 2(a). Name of Person Filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P.

(b)

Item 2(b). Address of Principal Business Office, or if None, Residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

(c)

Item 2(c). Citizenship: Deerfield Mgmt, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund IV, L.P. - Delaware limited partnerships; James E. Flynn – United States citizen

(d)

Item 2(d). Title of Class of Securities: Common Stock

(e)

Item 2(e). CUSIP Number: 28036F105 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in Section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) Investment company registered under Section 8 of the Investment Company Act. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; CUSIP No. 28036F105 13G Page 7 of 11 (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________ Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned**: Deerfield Mgmt, L.P. - 545,455 shares Deerfield Mgmt IV, L.P. – 3,933,137 shares Deerfield Management Company, L.P. - 4,478,592 shares Deerfield Partners, L.P. - 545,455 shares Deerfield Private Design Fund IV, L.P. – 3,933,137 shares James E. Flynn – 4,478,592 shares (b) Percent of class**: Deerfield Mgmt, L.P. – 0.64% Deerfield Mgmt IV, L.P. – 4.61% Deerfield Management Company, L.P. – 5.25% Deerfield Partners, L.P. - 0.64% Deerfield Private Design Fund IV, L.P. – 4.61%

View Full Filing

View this SC 13G/A filing on SEC EDGAR